Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is April 17, 2025, covering a share repurchase executed on April 16, 2025. The transaction was conducted through Citigroup Global Markets Limited as part of an existing buyback programme established via a non-discretionary agreement on February 24, 2025.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial performance metrics such as revenue or profit.
- Shares Purchased (April 16, 2025): 676,221 ordinary shares.
- Price Range: Lowest price paid was 1,327.00 GBp; highest price paid was 1,352.00 GBp.
- Volume-Weighted Average Price: 1,338.67 GBp.
- Programme Progress: Since the programme's inception on February 24, 2025, GSK has purchased a total of 29,901,322 ordinary shares.
- Treasury Shares Held: 198,971,625 ordinary shares.
- Shares in Issue (excluding Treasury): 4,116,263,530 ordinary shares.
- Total Voting Rights: 4,116,263,530.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury shares resulting from the April 16 repurchase. The filing does not provide comparative financial data (e.g., revenue or earnings) against prior periods, as it is a transactional disclosure rather than a periodic financial report.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding future operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described in the "Risk factors" section (pages 277 to 285) of the GSK 2024 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since February 24, 2025 (29,901,322 shares).
- Confirm the current number of shares in issue excluding treasury shares (4,116,263,530) for ownership percentage calculations.
- Review the GSK 2024 Annual Report on Form 20-F (pages 277-285) for detailed risk factors associated with forward-looking statements.
- Monitor future 6-K filings for updates on the remaining capacity or status of the share buyback programme.